Did you know?

About TransCode Therapeutics TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the Company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of …Feb 28, 2023 · BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company TM committed to more effectively treating cancer using RNA therapeutics, announced ... TransCode Therapeutics, Inc. 0.2620. +0.0020. +0.77%. BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed ...AboutTransCodeTherapeutics. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of ...Traders immediately bid up the RNAZ stock price this morning. It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ) stock. That’s because the company just disclosed the ...According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each. This has the company expecting to raise $8 million in gross proceeds from the ...TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ...Transcode Therapeutics Stock Forecast, RNAZ stock price prediction. Price target in 14 days: 0.267 USD. The best long-term & short-term Transcode ...RNAZ's stock price has decreased by -97.55% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 1 stock analyst, the 12-month stock price forecast for RNAZ stock stock is $3.00, which predicts an increase of 1,150.52%.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating …Discover historical prices for RNAZ stock on Yahoo Finance. View daily, weekly or monthly format back to when TransCode Therapeutics, Inc. stock was issued.52-week price history of RNAZ Stock. A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. TransCode Therapeutics Inc’s current trading price is -99.06% away from its 52-week high, while its distance from the 52-week low is 46.59%.Get the latest Transcode Therapeutics Inc (RNAZ) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Get Transcode Therapeutics Inc (RNAZ.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... TransCode Therapeutics, Inc. is a ...PTC Therapeutics (NASDAQ: PTCT) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with ...Sep 25, 2023 · By Ben Glickman. Shares of TransCode Therapeutics jumped Monday after reporting positive study results for its lead cancer treatment candidate. The stock was up 96% at $1.30 in morning trading. Oct 24, 2023 · Evidence of Drug Accumulation in Metastatic Lesions. BOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced preliminary results with its lead therapeutic candidate, TTX-MC138, in the first patient enrolled in its Phase 0 clinical trial aimed at ... TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...Oct 30, 2023 · TransCode Therapeutics, Inc. 0.3599. TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has closed a regis 4 giờ trước ... BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to ... BOSTON, April 14, 2023 (GLOBE NEWSWIRE) - TransCode Therapeutics Announces Closing of $8.5 Million Public Offering. BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously …Find out all the key statistics for TransCode Therapeutics, Inc. (RNAZ), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. ... Stock Price ... TransCode Therapeutics Reports Third Quarter 2023

TransCode Therapeutics, Inc. Common Stock (RNAZ) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. Nov. 23: CI TransCode Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 14: CI The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ...TransCode’s Chief Technology Officer and co-founder, Dr. Zdravka Medarova, said, “TTX-MC138 is a first-in-class therapeutic candidate against cancer, not only because of its molecular ...BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ...TransCode Therapeutics (NASDAQ: RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won’t pursue a plan to sell 12 ...Sep 26, 2023 · TransCode Therapeutics, Inc. BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively ... …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. TransCode Therapeutics, Inc.: TransCode Therapeutics An. Possible cause: TransCode Therapeutics, Inc. 0.2620. +0.0020. +0.77%. BOSTON, June 06, 2023.